athenahealth, Inc (NASDAQ:ATHN) had its price target increased by Robert W. Baird from $140.00 to $160.00 in a research report issued to clients and investors on Thursday. The firm currently has an “outperform” rating on the health services provider’s stock. Robert W. Baird’s price target would indicate a potential upside of 19.32% from the company’s current price.

Several other equities research analysts also recently commented on the stock. Jefferies Group LLC restated a “sell” rating and issued a $95.00 target price on shares of athenahealth in a research note on Friday, March 24th. Piper Jaffray Companies restated an “overweight” rating and issued a $160.00 target price on shares of athenahealth in a research note on Tuesday, April 4th. Cantor Fitzgerald restated a “buy” rating and issued a $118.00 target price (down previously from $135.00) on shares of athenahealth in a research note on Thursday, April 27th. Citigroup Inc set a $128.00 target price on shares of athenahealth and gave the company a “buy” rating in a research note on Monday, May 1st. Finally, Barclays PLC set a $88.00 target price on shares of athenahealth and gave the company an “underweight” rating in a research note on Monday, May 1st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $135.05.

Analyst Recommendations for athenahealth (NASDAQ:ATHN)

athenahealth (NASDAQ:ATHN) traded up 0.56% during mid-day trading on Thursday, hitting $134.09. 366,997 shares of the company were exchanged. The company has a market cap of $5.34 billion, a price-to-earnings ratio of 263.96 and a beta of 1.77. athenahealth has a 12-month low of $90.11 and a 12-month high of $142.40. The stock’s 50 day moving average is $114.85 and its 200-day moving average is $112.11.

athenahealth (NASDAQ:ATHN) last issued its earnings results on Thursday, April 27th. The health services provider reported $0.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.11 by $0.01. athenahealth had a net margin of 1.94% and a return on equity of 6.41%. The firm had revenue of $285.40 million during the quarter, compared to analyst estimates of $296.49 million. During the same quarter in the prior year, the firm posted $0.34 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. Equities research analysts predict that athenahealth will post $1.89 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/05/26/robert-w-baird-increases-athenahealth-inc-athn-price-target-to-160-00.html.

In other athenahealth news, SVP Jonathan D. Porter sold 300 shares of the business’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $109.48, for a total transaction of $32,844.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jonathan Bush sold 8,000 shares of the business’s stock in a transaction dated Tuesday, April 25th. The stock was sold at an average price of $120.00, for a total value of $960,000.00. Following the sale, the chief executive officer now directly owns 319,807 shares of the company’s stock, valued at $38,376,840. The disclosure for this sale can be found here. Insiders have sold a total of 16,331 shares of company stock valued at $2,020,274 over the last three months. Company insiders own 3.04% of the company’s stock.

A number of hedge funds have recently made changes to their positions in ATHN. BlackRock Inc. boosted its stake in shares of athenahealth by 30,642.6% in the first quarter. BlackRock Inc. now owns 1,599,847 shares of the health services provider’s stock valued at $180,286,000 after buying an additional 1,594,643 shares in the last quarter. Janus Capital Management LLC boosted its stake in shares of athenahealth by 18.1% in the fourth quarter. Janus Capital Management LLC now owns 5,738,978 shares of the health services provider’s stock valued at $603,596,000 after buying an additional 878,970 shares in the last quarter. Morgan Stanley boosted its stake in shares of athenahealth by 9.7% in the first quarter. Morgan Stanley now owns 4,514,305 shares of the health services provider’s stock valued at $508,717,000 after buying an additional 397,837 shares in the last quarter. Camber Capital Management LLC purchased a new stake in shares of athenahealth during the fourth quarter valued at $31,551,000. Finally, Arrowpoint Asset Management LLC boosted its stake in shares of athenahealth by 149.1% in the fourth quarter. Arrowpoint Asset Management LLC now owns 454,069 shares of the health services provider’s stock valued at $47,754,000 after buying an additional 271,759 shares in the last quarter.

About athenahealth

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

12 Month Chart for NASDAQ:ATHN

Receive News & Ratings for athenahealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.